Bahrain Approves Use of Oral COVID-19 Antiviral, Paxlovid

  • Publish date: Monday، 03 January 2022
Bahrain Approves Use of Oral COVID-19 Antiviral, Paxlovid
Related articles
Bahrain Approves Booster Shots for Those Aged 12 to 17
Bahrain Tops Global COVID-19 Recovery Index
The Updated Bahrain COVID-19 Protocols

The National Health Regulatory Authority (NHRA) in Bahrain on January 1 approved the emergency use of the oral COVID-19 antiviral, Paxlovid, with the medication expected to arrive in January.

The medication has been authorised for individuals 18 years old and above who suffer from mild to moderate symptoms and are at an increased risk of developing severe COVID-19 that may lead to mortality.

Paxlovid consists of two, co-packaged antiviral medicine (PF-07321332 and Ritonavir) that are designed to stop the virus causing COVID-19 from multiplying in the body and therefore help those infected to overcome the viral infection.

The decision follows the evaluation of data provided by the manufacturer Pfizer, carried out by the NHRA's Pharmaceutical Products Regulation Department (PPR).